Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects

Clinical Pharmacokinetics

Volumn 45, Issue 8, 2006, Pages 821-841

  Khosravan, Reza ^a,b   Grabowski, Brian A ^a   Wu, Jing Tao ^a   Joseph Ridge, Nancy ^a   Vernillet, Laurent ^a  

^a TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; FEBUXOSTAT; HYPOXANTHINE; PLACEBO; URIC ACID; XANTHINE; XANTHINE OXIDASE INHIBITOR;

ABDOMINAL PAIN; ADULT; ALLERGIC REACTION; ARTICLE; ASTHENIA; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSPEPSIA; DYSPNEA; ECG ABNORMALITY; FEMALE; FEVER; FLUSHING; GLUCURONIDATION; GOUT; HEADACHE; HUMAN; HYPERURICEMIA; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; OXIDATION; PARAMETER; PERIPHERAL VASCULAR DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TACHYCARDIA; URINALYSIS; URINARY EXCRETION; VASODILATATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; GOUT SUPPRESSANTS; HUMANS; HYPOXANTHINE; MALE; MODELS, BIOLOGICAL; THIAZOLES; URIC ACID; XANTHINE; XANTHINE OXIDASE;

EID: 33746865996     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645080-00005     Document Type: Article

References (39)

1. Roubenoff R, Klag MJ, Mead LA, et al. Incidence and risk factors for gout in white men. JAMA 1991; 266: 3004-7
2. Wortmann RL, Kelley WN. Gout and hyperuricemia. In: Ruddy S, Harris Jr ED, Sledge CB, editors. Kelley's textbook of rheumatology. 6th ed. Philadelphia (PA): WB Saunders Company, 2001: 1339-1376
3. Emmerson BT. The management of gout. N Engl J Med 1996; 334: 445-51
4. Wyngaarden JB, Kelly WN. Gout. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, et al., editors. Metabolic basis of inherited disease. 5th ed. New York: McGraw-Hill Book Co, 1982: 1043
5. Benedict JD, Forsham PH, Stetten D. The metabolism of uric acid in normal and gouty human studies with the aid of isotopic uric acid. J Biol Chem 1949; 181: 183-93
6. Benedict JD, Roche M, Yu TF, et al. Incorporation of glycine nitrogen into uric acid in normal and gouty man. Metabolism 1952; 1: 3-12
7. Scott JT, Holloway VP, Glass HI, et al. Studies of uric acid pool size and turnover rate. Ann Rheum Dis 1969 Jul; 28 (4): 366-73
8. Scott JT. Gout: the last 50 years. J R Soc Med 1996; 89: 634-7
9. Star VL, Hochberg MC. Prevention and management of gout. Drugs 1993; 45: 212-22
10. De Bont M, Pieters R. Management of hyperuricemia with rasburicase review. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1431-40
11. Okamoto K, Eger BT, Nishino T, et al. An extremely potent inhibitor of xanthine oxidoreductase: crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 2003; 278: 1848-55
12. Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005; 76: 1835-47
13. Osada Y, Tsuchimoto M, Fukushima H, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol 1993; 241: 183-8
14. Komoriya K, Osada Y, Hasegawa M, et al. Hypouricemic effect of allopurinol and the novel xanthine oxides inhibitor TEI-6720 in chimpanzees. Eur J Pharmacol 1993; 250: 455-60
15. Horiuchi H, Ota M, Kobayashi M, et al. A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats. Res Commun Mol Pathol Pharmacol 1999; 104: 307-19
16. Becker MA, Kisicki J, Khosravan R, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1111-6
17. Kubo J, Yonezawa H, Mizuno H, et al. Pharmacodynamics of TMX-67 (TEI-6720), a novel xanthine dehydrogenase/oxidase inhibitor, in man. Clin Biochem 1997; 30: 265
18. Komoriya K, Hoshide S, Takeda K, et al. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NP-SIXO) in patients with gout and/or hyperuricemia. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1119-22
19. Ishiwata Y, Kubo J, Komoriya K, et al. TMX-67 a novel xanthine oxidase/xanthine dehydrogenase (XOD) inhibitor, shows strong uric acid lowering action in patients with hyperuricemia and gout [abstract]. Arthritis Rheum 2001; 44: S129
20. Kamatani N, Fujimori S, Hada T, et al. Phase II dose response clinical trial using febuxostat (TMX-67), a novel-type xanthine oxidase/xanthine dehydrogenase inhibitor, for gout and hyperuricemia [abstract]. Arthritis Rheum 2003; 48: S530
21. Kondo S, Nishimura S, Mochizuki T, et al. Metabolic fate of [14C]-TEI-6720, a novel xanthine oxidase inhibitor: tissue distribution after oral administration in rats, protein binding and metabolism in vivo and in vitro [abstract]. Drug Metab Rev 1995; 8: 56
22. Hoshide S, Nishimura S, Ishii S, et al. Metabolites of TMX-67, a new pharmaceutical entity for the treatment of gout or hyperuricemia, and their pharmacokinetic profiles in human [abstract]. Drug Metab Rev 2000; 32: 269
23. Grabowski B, Khosravan R, Vernillet L, et al. Pharmacokinetics, pharmacodynamics, and safety of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase, in healthy subjects [abstract]. J Clin Pharmacol 2004; 44: 1196
24. Khosravan R, Bopp BA, Cox MA, et al. Dose-related decreases in uric acid observed in a multiple-dose safety, pharmacokinetic, and pharmacodynamic study of TMX-67, anovel xanthine oxidase/dehydrogenase inhibitor, in healthy subjects [abstract]. Arthritis Rheum 2000; 43: S401
25. Mayer MD, Khosravan R, Vernillet L, et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 2005; 12: 22-34
26. Khosravan R, Grabowski B, Mayer MD, et al. Effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat [abstract]. Clin Pharmacol 2005; 45: 1083
27. Khosravan R, Kukulka B, Wu JT, et al. Effects of age and gender on febuxostat pharmacokinetics, pharmacodynamics, and safety in healthy subjects [abstract]. Clin Pharmacol Ther 2005; 77: P50
28. Hende KR, Noone RM, Stome WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76: 47-56
29. Turnheim K, Privanek P, Oberbauer R. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young. Br J Clin Pharmacol 1999; 48: 501-9
30. Khosravan R, Erdman K, Vernillet L, et al. Effect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate, in healthy subjects [abstract]. Clin Pharmacol Ther 2005; 77: P43
31. Khosravan R, Mayer MD, Wu JT, et al. Effect of concomitant administration of febuxostat and colchicine on pharmacokinetics of febuxostat and colchicine at steady state [abstract]. Arthritis Rheum 2005; 52: S102-3
32. Khosravan R, Wu JT, Joseph-Ridge, et al. Effect of concomitant administration of febuxostat with naproxen or indomethacin on pharmacokinetics of febuxostat, naproxen, or indomethacin at steady state [abstract]. Arthritis Rheum 2005; 52: S103
33. Khosravan R, Wu JT, Lademacher C, et al. Effect of febuxostat on pharmacokinetics and pharmacodynamics of warfarin [abstract]. J Clin Pharmacol 2005; 45: 1084
34. Cotran RS, Kumar V, Robbins SL. Robbins pathologic basis of disease. 4th ed. Philadelphia (PA): WB Saunders, 1989: 1359
35. Seegmiller JE. Xanthine stone formation. Am J Med 1968; 45: 780-3
36. Mandel GS, Mandel NS. Analysis of stones. In: Coe FL, Favous MJ, Pak CYC, et al. editors. Renal stones: medical and surgical management. Philadelphia (PA): Lippincott-Raven, 1996: 323-335
37. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005; 52: 916-23
38. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450-61
39. Yu P, Khosravan R, MacDonald P, et al. Effect of febuxostat, a novel non-purine, selective inhibitor of xanthine oxidase, on the QT interval in healthy subjects [abstract]. J Clin Pharmacol 2004; 44: 1195